PDCD1 and non-small cell lung carcinoma: By blocking key receptors facilitating inhibitory signalling pathways of the immune system, such as programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1), immune checkpoint blockade (ICB) has demonstrated encouraging responses in NSCLC patients [9,10].